TY - JOUR
T1 - Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma
T2 - An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo
AU - Olivieri, A.
AU - Marchetti, M.
AU - Lemoli, R.
AU - Tarella, C.
AU - Iacone, A.
AU - Lanza, F.
AU - Rambaldi, A.
AU - Bosi, A.
PY - 2012/3
Y1 - 2012/3
N2 - Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization. Identification of poor mobilizers (PMs) would provide a tool for early intervention with new mobilization agents. The Gruppo italianoTrapianto di Midollo Osseo working group proposed a definition of PMs applicable to clinical trials and clinical practice. The analytic hierarchy process, a method for group decision making, was used in setting prioritized criteria. Lymphoma or myeloma patients were defined as 'proven PM' when: (1) after adequate mobilization (G-CSF 10 μg/kg if used alone or ≥5 μg/kg after chemotherapy) circulating CD34 + cell peak is 6 CD34 + cells per kg in ≤3 apheresis. Patients were defined as predicted PMs if: (1) they failed a previous collection attempt (not otherwise specified); (2) they previously received extensive radiotherapy or full courses of therapy affecting SC mobilization; and (3) they met two of the following criteria: advanced disease (≥2 lines of chemotherapy), refractory disease, extensive BM involvement or cellularity
AB - Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization. Identification of poor mobilizers (PMs) would provide a tool for early intervention with new mobilization agents. The Gruppo italianoTrapianto di Midollo Osseo working group proposed a definition of PMs applicable to clinical trials and clinical practice. The analytic hierarchy process, a method for group decision making, was used in setting prioritized criteria. Lymphoma or myeloma patients were defined as 'proven PM' when: (1) after adequate mobilization (G-CSF 10 μg/kg if used alone or ≥5 μg/kg after chemotherapy) circulating CD34 + cell peak is 6 CD34 + cells per kg in ≤3 apheresis. Patients were defined as predicted PMs if: (1) they failed a previous collection attempt (not otherwise specified); (2) they previously received extensive radiotherapy or full courses of therapy affecting SC mobilization; and (3) they met two of the following criteria: advanced disease (≥2 lines of chemotherapy), refractory disease, extensive BM involvement or cellularity
KW - autologous transplantation
KW - consensus conference
KW - lymphoma
KW - multiple myeloma
KW - stem cell mobilization
UR - http://www.scopus.com/inward/record.url?scp=84858076675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858076675&partnerID=8YFLogxK
U2 - 10.1038/bmt.2011.82
DO - 10.1038/bmt.2011.82
M3 - Article
C2 - 21625224
AN - SCOPUS:84858076675
VL - 47
SP - 342
EP - 351
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 3
ER -